Medicine and Dentistry
Cohort Analysis
100%
Diffuse Large B-Cell Lymphoma
65%
Non-Hodgkin Lymphoma
64%
Hodgkin's Lymphoma
57%
Drug Megadose
51%
Psychoactive Drug
49%
Overall Survival
48%
Hazard Ratio
38%
Acute Myeloid Leukemia
38%
B-Cell Lymphoma
38%
Drug Use
38%
Methotrexate
38%
Myeloproliferative Neoplasm
38%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
31%
Follicular Lymphoma
28%
Acute Leukemia
28%
Assisted Reproductive Technology
28%
Cancer
24%
Mental Health
22%
Patient with Non-Hodgkins Lymphoma
20%
Diseases
20%
Population
20%
Burkitt's Lymphoma
19%
Systematic Review
19%
Health Care
19%
Osteoporosis
19%
Diabetes
19%
Clinical Trial
19%
Somatics
19%
Loss of Function Mutation
19%
Diabetes Mellitus
19%
Eosinophilic Esophagitis
19%
Central Nervous System
19%
Reproductive Medicine
19%
Classical Hodgkin Lymphoma
19%
Silo-Filler's Disease
19%
Glycon
19%
Case-Control Study
19%
Mastocytosis
19%
Prevalence
19%
Birth Rate
19%
Survivorship in Cancer Care
16%
Progression Free Survival
16%
Event Free Survival
14%
Cumulative Incidence
13%
Bleomycin
13%
Proportional Hazards Model
12%
Prednisolone
11%
Malignant Neoplasm
11%
Childbirth
10%
Keyphrases
National Cohort Study
59%
Lymphoma Patients
52%
Denmark
41%
Reproduction Pattern
38%
Background Population
38%
High Risk
33%
Danish Population
30%
Adult Patients
25%
Lymphoma
24%
Population-based Study
23%
Eosinophilic Esophagitis
19%
Osteoporosis
19%
Sweden
19%
Population-based
19%
Acute Myeloid Leukemia
19%
Norway
19%
High-dose Methotrexate (HD-MTX)
19%
Aggressive Course
19%
Splenic Diffuse Red Pulp Lymphoma
19%
CNS Prophylaxis
19%
Psychotropic Drug Use
19%
Overall Survival
19%
Hodgkin Lymphoma Survivors
19%
Aggressive B-cell Lymphoma
19%
Childbirth
19%
Hodgkin Lymphoma
19%
Temporal Change
19%
Matched Cohort Study
19%
Cumulative Risk
19%
Pulmonary Disease
19%
Classical Hodgkin Lymphoma
19%
Metformin Use
19%
Mastocytosis
19%
Nationwide Register Study
19%
Confidence Interval
16%
Hazard Ratio
16%
EFS24
15%
Risk Factors
13%
Danish National Patient Registry
12%
Central Nervous System Relapse
12%
Bleomycin
11%
Incidence Rate
10%
Diffuse Large B-cell Lymphoma (DLBCL)
9%
Bone Health
9%
Non-Hodgkin Lymphoma
9%
Female Sex
9%
Female Age
9%
Lymphoma Survivors
9%
Aggressive non-Hodgkin Lymphoma
9%
Reproductive Patterns
9%
Pharmacology, Toxicology and Pharmaceutical Science
Psychotropic Agent
68%
Cohort Study
59%
Acute Myeloid Leukemia
57%
Nonhodgkin Lymphoma
38%
Follicular Lymphoma
38%
Case-Control Study
38%
Myeloproliferative Neoplasm
38%
Overall Survival
35%
Diffuse Large B Cell Lymphoma
33%
Remission
21%
Patient Registry
19%
Clinical Trial
19%
Myelodysplastic Syndrome
19%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
19%
Eosinophilic Esophagitis
19%
B Cell Lymphoma
19%
Methotrexate
19%
Hodgkin Disease
19%
Prednisolone
19%
Classical Hodgkin Lymphoma
19%
Metformin
19%
Malignant Neoplasm
18%
Progression Free Survival
14%
Statin (Protein)
11%
Disease
9%
Antidepressant
7%
Typical Antipsychotic
7%
Distress Syndrome
5%
Automutilation
5%
Comorbidity
5%
